Lunit Raises $200M to Revolutionize Cancer Diagnosis with AI-Driven Radiology Solutions

We are thrilled to announce that Lunit, a leading public company dedicated to conquering cancer through AI, has successfully raised $200,000,000 in our latest funding round. This remarkable milestone not only reaffirms the trust investors have in our mission but also provides the fuel we need to further enhance our state-of-the-art medical AI solutions. At Lunit, we are committed to revolutionizing cancer care with diagnostic tools that empower healthcare professionals by elevating diagnostic performance and treatment planning. Our advanced AI suite for radiology—comprising Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, Lunit INSIGHT DBT for digital breast tomosynthesis, and our specialized Lunit CXR Triage system for use in emergency departments—has been rigorously validated through more than 100 publications in reputable peer-reviewed journals such as JAMA Oncology, Lancet Digital Health, and Radiology. Today, our solutions are trusted by over 3,500 medical sites globally, making a tangible difference in early cancer detection and effective treatment strategies. The newly secured capital will be strategically deployed to drive further innovation in our AI technologies, expand our clinical footprint across new markets, and invest in continued research and development initiatives. With these funds, we aim to refine our products, enhance performance metrics, and extend our reach into more healthcare systems worldwide, ultimately improving patient outcomes on a global scale. At Lunit, our vision is clear: to empower clinicians and transform the landscape of cancer screening and treatment with the power of artificial intelligence. We are excited about what the future holds as we continue to push the boundaries of medical technology and create life-changing advances for patients everywhere.